Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Zafgen Announces New Weight Loss and Safety Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015
Zafgen Announces New Weight Loss and Safety Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015
Zafgen Announces New Weight Loss and Safety Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015
Submitted by
admin
on March 8, 2015 - 10:18am
Source:
Yahoo
News Tags:
Zafgen
hypothalamic injury-associated obesity
beloranib
Headline:
Zafgen Announces New Weight Loss and Safety Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015
Do Not Allow Advertisers to Use My Personal information
